CAMBRIDGE, Mass.--(BUSINESS WIRE)--Repertoire Immune Medicines, a clinical-stage biotech company decoding the immune synapse to create novel immune therapies for cancer, immune disorders, infectious ...
However, when two or more foci of prostate cancer separated by intervening benign tissue are present in a single core biopsy, there is currently no consensus dictating the optimal method to report ...
MINNEAPOLIS, March 7, 2017 /PRNewswire/ -- Bio-Techne has entered into an exclusive license agreement with Multiclonal Therapeutics (MCT) to commercialize reagents and media systems in the research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results